No ASX ETF holds Avecho (AVE) as of 15 Oct 2026. Over the last year it rose 114.3%: on $10,000, +$11429. We explain 3 big moves in that time.
About AVE
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$65.7m
- Held by0 ETFs
- Big moves3 in 1Y
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +20.0%30 Jun 2026· Sector Flow
Avicho Biotechnology's stock rose 20% likely due to a broad-sector surge in ASX biotech/medical innovation stocks, highlighted by Neuren Pharmaceuticals' 35% jump and subsequent sector-wide investor interest.
- +40.0%24 Jun 2026· Operational
Avecho announced positive interim Phase III insomnia trial results, driving a 40% share price surge.
- +20.0%27 Nov 2025· Unknown
No clear news explains the 20% surge in Avicho Biotechnology shares on 26 Nov 2025; the provided articles are all real estate stories unrelated to the company.
Held by 0 ETFs
No ETF we track holds AVE directly.
Other Health Care companies
- SHLSonic Healthcare47 ETFs
- RMDResMed44 ETFs
- CSLCSL Limited42 ETFs
- BDXBcal36 ETFs
- CSXCleanspace36 ETFs
- REGRegis Health33 ETFs
- TLXTelix Pharma32 ETFs
- SIGSigma Healthcare31 ETFs
Why did AVE rise 20.0% on 27 Nov 2025?
Avecho
No clear news explains the 20% surge in Avicho Biotechnology shares on 26 Nov 2025; the provided articles are all real estate stories unrelated to the company.
The supplied news articles cover only real estate topics (house sales, auctions) and contain no reference to Avicho Biotechnology, its sector, or any corporate event. The abnormal price move and high volume suggest a company-specific announcement or market activity, but no evidence is available to identify a cause. Therefore, certainty is very low.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
News coverage